Related Experiment Video
Updated: Jun 27, 2026
08:12
Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
Published on: February 2, 2022
[Surgery for pancreatic cancer]
T Welsch1, M W Büchler, J Schmidt
1Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universität Heidelberg.
Zeitschrift Fur Gastroenterologie
|December 5, 2008
Summary
Pancreatic ductal adenocarcinoma has a poor prognosis due to aggressive growth and treatment resistance. Achieving R0 resection and N0 stage offers the best survival outcomes for patients.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Context:
- Pancreatic ductal adenocarcinomas are the fourth most common fatal cancer, with survival rates below 5% overall.
- Despite resection and chemotherapy, 5-year survival remains low (20-25%) due to aggressive tumor growth, early metastasis, and high rates of positive resection margins (75%).
- Surgical complications like pancreatic fistulas (up to 10%) and challenges in pancreatic anastomosis contribute to poor outcomes.
Purpose:
- To review current surgical strategies and evidence-based data for improving treatment outcomes in pancreatic cancer.
- To highlight the importance of R0 resection and N0 stage for optimal patient prognosis.
- To emphasize the role of neoadjuvant therapy and clinical trial enrollment for advancing pancreatic cancer treatment.
Summary:
- Pancreatic ductal adenocarcinomas exhibit aggressive infiltrative growth, leading to high rates of positive resection margins and local recurrence.
- Standard surgical procedures include pylorus-preserving pancreatoduodenectomy and left pancreatic resection. High-volume centers report improved survival and reduced mortality.
- While portal vein infiltration is manageable with vascular reconstruction, radical lymphadenectomy is not supported by current data. Neoadjuvant therapy may benefit selected patients.
Impact:
- Achieving an R0 resection (no residual tumor) and N0 stage (no lymph node metastasis) are critical prognostic factors, correlating with a median survival of 2 years and good quality of life.
- Pancreas surgery is increasingly guided by evidence from randomized controlled trials.
- Enrollment in clinical studies for neoadjuvant, surgical, or adjuvant therapies is crucial for further improving treatment results and patient survival.
